Evidence map›Paper›PMID 41828454›Full record

ReviewInternational journal of molecular sciences2026

Targeting Autophagy for Otoprotection: Translating Basic Mechanisms into Clinical Strategies.

Fei Wang, Tiantian Zhang, Bin Bai, Lian Hui, Yan Wang, Jian Zang

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fei WangDepartment of Otolaryngology, The First Hospital of China Medical University, Shenyang 110001, China.ORCID 0009-0003-3653-213X
Tiantian ZhangDepartment of Geriatrics, The First Hospital of China Medical University, Shenyang 110001, China.
Bin BaiDepartment of Dermatology, The First Hospital of China Medical University, Key Laboratory of Immunodermatology, Ministry of Education and NHC, National Joint Engineering Research Center for Theranostics of Immunological Skin Diseases, Shenyang 110001, China.
Lian HuiDepartment of Otolaryngology, The First Hospital of China Medical University, Shenyang 110001, China.
Yan WangDepartment of Otolaryngology, The First Hospital of China Medical University, Shenyang 110001, China.
Jian ZangDepartment of Otolaryngology, The First Hospital of China Medical University, Shenyang 110001, China.

Funding

Natural Science Foundation of Liaoning Province Grant No.2024-BS-064
6 · The paper itself

Abstract

Sensorineural hearing loss (SNHL), the predominant form of global hearing impairment, stems from the irreversible loss of inner ear sensory cells and neurons. Since mammalian cochlea lacks regenerative capacity, cell death represents a final common pathway for diverse insults. Current therapies are merely compensatory, underscoring an urgent need for mechanistic, targeted interventions. Autophagy, a critical homeostatic process, plays complex and dynamic roles in the cochleae. This review synthesizes current evidence on its regulation, highlighting its stage-specific and dual roles in SNHL. We emphasize mitophagy and its context-dependent effects on cell survival. Critically, we discuss an emerging therapeutic paradigm: a dual-phase autophagy modulation strategy. This approach proposes enhancing cytoprotective autophagy in early stages to maintain homeostasis, while inhibiting excessive autophagic flux later to prevent catastrophic cell death. This precision-targeting framework holds significant promise for guiding novel drug development and future clinical translation, moving beyond symptomatic management towards transformative treatment.

Indexed as

AutophagyHearing Loss, SensorineuralAnimalsCochleaHumansMitophagySignal TransductionTOR Serine-Threonine KinasesTOR Serine-Threonine KinasesautophagymitophagymTOR signalingpexophagysensorineural hearing losstherapeutic targets

Identifiers

PMID41828454
PMCPMC12984700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.